RxDoctor Payments Data

Cori Lopez, DO

Family Medicine · Cheney, WANPI 1487875647

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, GSK. That places this record below the midpoint for family medicine clinicians in WA, where the typical reported total is $103.

$18in general payments, 2019–2025

Across 1 payment — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$18
$165,378in research payments, 2019–2025

Across 16 payments — averaging $10,336 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$165K

What the payments were for

  • Food & beverage$18100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$18

How this compares

$18 in reported general payments places this provider in the 10th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$106,221
Medicare patients
285
Services billed
2,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$62,693
EliquisApixaban47$61,788
FarxigaDapagliflozin Propanediol18$22,662
MyrbetriqMirabegron31$20,077
OzempicSemaglutide14$19,189
LinzessLinaclotide11$16,570
Breo ElliptaFluticasone/Vilanterol16$11,834
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$10,535
Arnuity ElliptaFluticasone Furoate23$7,819
Humalog Kwikpen U-100Insulin Lispro12$4,903
Atorvastatin Calcium394$4,521
Novolog FlexpenInsulin Aspart13$4,423
Incruse ElliptaUmeclidinium Bromide11$4,003
Albuterol Sulfate HfaAlbuterol Sulfate82$3,628
Levothyroxine Sodium301$3,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta, Incruse Ellipta$18$23,65750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Cheney

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →